Enovis (ENOV) Set to Announce Quarterly Earnings on Tuesday

Enovis (NYSE:ENOV) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, November 7th. Analysts expect the company to announce earnings of $0.52 per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, August 3rd. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.53 by $0.08. The business had revenue of $428.50 million during the quarter, compared to analysts’ expectations of $420.06 million. Enovis had a negative net margin of 8.52% and a positive return on equity of 3.74%. The company’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.59 EPS. On average, analysts expect Enovis to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Enovis Price Performance

Enovis stock opened at $47.02 on Friday. The stock has a market cap of $2.56 billion, a P/E ratio of -18.44 and a beta of 2.01. The company has a fifty day simple moving average of $50.77 and a 200-day simple moving average of $56.12. Enovis has a 12-month low of $43.04 and a 12-month high of $66.71. The company has a current ratio of 2.51, a quick ratio of 1.23 and a debt-to-equity ratio of 0.12.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Robert W. Baird lifted their price objective on shares of Enovis from $67.00 to $70.00 and gave the stock an “outperform” rating in a research report on Friday, August 4th. Roth Mkm began coverage on shares of Enovis in a research report on Friday, October 20th. They issued a “buy” rating and a $75.00 price target for the company. Finally, Needham & Company LLC reissued a “buy” rating and issued a $70.00 price target on shares of Enovis in a research report on Friday, October 20th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $69.17.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN increased its stake in Enovis by 0.5% in the second quarter. Wells Fargo & Company MN now owns 33,267 shares of the company’s stock valued at $2,133,000 after purchasing an additional 178 shares during the period. Gamco Investors INC. ET AL increased its stake in Enovis by 3.2% in the fourth quarter. Gamco Investors INC. ET AL now owns 8,523 shares of the company’s stock valued at $456,000 after purchasing an additional 266 shares during the period. Alliancebernstein L.P. increased its stake in Enovis by 0.4% in the fourth quarter. Alliancebernstein L.P. now owns 67,786 shares of the company’s stock valued at $3,628,000 after purchasing an additional 279 shares during the period. Pathstone Family Office LLC increased its stake in Enovis by 3.3% in the third quarter. Pathstone Family Office LLC now owns 8,970 shares of the company’s stock valued at $459,000 after purchasing an additional 286 shares during the period. Finally, Public Employees Retirement System of Ohio increased its stake in Enovis by 1.2% in the third quarter. Public Employees Retirement System of Ohio now owns 27,145 shares of the company’s stock valued at $1,251,000 after purchasing an additional 332 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufacture and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.